Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyLeukemiaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.
April 4
 · 
Reactions
MyLeukemiaTeam

Can the new government-approved drug be used for people with CMML-1?

The recently approved drugs mentioned are specifically for chronic myeloid leukemia (CML), not chronic myelomonocytic leukemia (CMML). These are two different types of leukemia with different treatment approaches.

The new drugs approved for CML include Show Full Answer

Can the new government-approved drug be used for people with CMML-1?

The recently approved drugs mentioned are specifically for chronic myeloid leukemia (CML), not chronic myelomonocytic leukemia (CMML). These are two different types of leukemia with different treatment approaches.

The new drugs approved for CML include:
* Asciminib (Scemblix) - approved in 2024 for newly diagnosed CML
* Danziten - a new formulation of nilotinib that can be taken with food
* Expanded approval of bosutinib for children with CML

For CMML-1 specifically, the FDA-approved chemotherapy drugs include:
* Vidaza (azacitidine)
* Dacogen (decitabine)
* Inqovi (decitabine and cedazuridine)

These medications don't cure CMML but may help normalize blood cell counts and reduce symptoms. Other options like stem cell transplantation may be considered depending on your age, health status, and how your leukemia is responding to treatment.

It's important to discuss with your healthcare team which treatments are appropriate for your specific situation with CMML-1.

April 4

Related Questions

View All
A MyLeukemiaTeam Member asked a question 💭
Australia

A MyLeukemiaTeam Member asked a question 💭
Australia

A MyLeukemiaTeam Member asked a question 💭
Australia